Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.80 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449625 | 0.89 | ADORA2A (1.00) | ADORA2AADORA1RORC | |
| SCHEMBL1449619 | 0.89 | ADORA2A (0.73) | ADORA2AADORA1RORCALDH1A1HSD17B10 | |
| SCHEMBL1449322 | 0.88 | ADORA2A (1.00) | ADORA2AADORA1RORCALDH1A1HSD17B10 | |
| SCHEMBL1449425 | 0.88 | ADORA2A (0.63) | ADORA2AADORA1RORCALDH1A1HSD17B10 | |
| SCHEMBL1449696 | 0.87 | ADORA2A (1.00) | ADORA2AADORA1ALDH1A1HSD17B10CYP1A2 | |
| Cyclopropane SCHEMBL15484617 | 0.86 | ADORA2A (0.81) | ADORA2AADORA1ALDH1A1HSD17B10CYP1A2 | |
| Cyclohexane SCHEMBL15484623 | 0.86 | ADORA2A (0.81) | ADORA2AADORA1ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL1449473 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1ALDH1A1 | |
| SCHEMBL1450041 | 0.86 | ADORA2A (0.78) | ADORA2AADORA1ALDH1A1HSD17B10MAPK1 | |
| SCHEMBL1450236 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | claimed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | claimed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | claimed |
| EP-1794157-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-06-13 | — | — | EP | claimed |
| WO-2006032273-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-30 | — | — | WO | claimed |
| EP-1794157-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-7910613-B2 | 2-acylaminothiazole derivatives | H. LUNDBECK A/S (DK) | 2011-03-22 | — | — | US | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | H. LUNDBECK A/S (DK) | 2009-05-28 | — | — | US | disclosed |
| EP-1799065-A1 | MAKE-UP METHOD USING A MAGNETIC COMPOSITION CONTAINING AT LEAST ONE TINTING AGENT HAVING OPTICAL PROPERTIES WHICH ARE SENSITIVE TO AN EXTERNAL STIMULUS | L'Oréal (FR) | 2007-06-27 | — | — | EP | disclosed |
| EP-1799064-A1 | METHOD FOR MAKING UP KERATINOUS MATERIALS AND KIT THEREFOR | L'Oréal (FR) | 2007-06-27 | — | — | EP | disclosed |
| EP-1799067-A1 | MAKE-UP METHOD USING A MAGNETIC COMPOSITION CONTAINING AT LEAST ONE DIFFRACTIVE PIGMENT | L'Oréal (FR) | 2007-06-27 | — | — | EP | disclosed |
| EP-1794157-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006037905-A1 | METHOD FOR MAKING UP KERATINOUS MATERIALS AND KIT THEREFOR | L'OREAL (FR) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006037902-A1 | MAKE-UP METHOD USING A MAGNETIC COMPOSITION CONTAINING AT LEAST ONE DIFFRACTIVE PIGMENT | L'OREAL (FR) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006037903-A1 | MAKE-UP METHOD USING A MAGNETIC COMPOSITION CONTAINING AT LEAST ONE TINTING AGENT HAVING OPTICAL PROPERTIES WHICH ARE SENSITIVE TO AN EXTERNAL STIMULUS | L'OREAL (FR) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006032273-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137642-A1 | 2-Acylaminothiazole Derivatives | ADORA2A, HTR2C, ADORA2B | ADORA2A 1/4885ADORA1 7/4885RORC 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.